retatrutide phase 2 diabetes trial ESC 2024: improves lipid and cardiovascular risk profile in II Retatrutide, a GIP, GLP-1 and
Description
(2007) Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes
01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)
Take our quick 2-minute assessment
This disease burden is compounded by a constellation of associated comorbidities, including hypertension [15], dyslipidemia [16], metabolic dysfunctionassociated steatotic liver disease (MASLD
The findings were based on a review conducted by the Food and Drug Administration using data from the FDA Adverse Event Reporting System (FAERS)
E.ChaneyM
